Effects of Sodium Glucose Co-Transporter-2 (SGLT-2) on self-reported symptoms and serum biomarkers in patients with diabetes and heart failure.

Endcrinology Department, Box Hill Hospital - Eastern Health0 个研究点目标入组 2 人开始时间: 2018年5月10日最近更新: 2019年1月28日

适应症

试验速览

暂无简介。

•Patients aged between 18 and 85 with established heart failure (New York Heart Association Class II, III, IV) AND
•-Receiving treatment for type 2 diabetes mellitus with metformin, a sulphonylurea, a dual oral therapy, a combination of insulin and oral agents or insulin alone in cases where oral antidiabetic medications are contraindicated.
•-The HbA1c measurements of participants should be greater than 7.0% and obtained within the preceding 4 months.
•- Endocrinology team have assessed and deemed the patient suitable to be commenced on SGLT-2 inhibitors as per current guidelines.

•-Patients with type 1 diabetes mellitus, stage 3B, 4 and 5 chronic kidney disease (including patients on dialysis), galactose intolerance and a history of alcohol misuse, ketoacidosis or recurrent genitourinary infections.
•-Patients already receiving treatment with a dipeptidyl peptidase 4 inhibitor, thiazolidinedione or a glucagon-like peptide-1 .

发起方

Endcrinology Department, Box Hill Hospital - Eastern Health